Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor ...

VAPING inside your home may not be as harmless as you thought. Though the cloud of vapour you exhale may only be visible for ...

【导读】肿瘤微环境中的一些代谢物可以改变固有免疫功能。9月26日，武汉大学李友军教授研究团队在期刊《Advanced Science》上发表了研究论文，题为“Increases in 4-Acetaminobutyric Acid Generated ...

Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301 ...

ABT-301, a novel HDAC inhibitor, has shown promising safety and pharmacokinetic profiles in a prior Phase 1 study as a single agent. Preclinical studies indicate that ABT-301 enhances the ...

Results from a preclinical study in mice and a collaborative clinical study in patients show that the type 2 immune response -- associated with parasitic infection and thought to play a negative role ...

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune ...

The following is a summary of “MATR3 Promotes Liver Cancer Progression by Suppressing DHX58–Mediated Type I Interferon ...

Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for ...

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and ...

Haroun stated“This theory is supported by the inhibitory activity of DeltaRex-G in transduced CD4+ CD8+ cell cultures. DeltaRex-G may be used to treat ... while retaining the efficacy of unaffected ...

Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024NEW YORK and ...